Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23870601 | 0.82 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL20326558 | 0.81 | CA1 (0.45) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL13490197 | 0.79 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL854273 | 0.78 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL25123692 | 0.78 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL843324 | 0.78 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL19750797 | 0.76 | CA1 (0.41) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL3940725 | 0.76 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL21025722 | 0.75 | ALDH1A1 (0.38) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL20315020 | 0.75 | CA14 (0.40) | HDAC6HDAC1HDAC2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683669-A2 | COMBINATIONS AND METHODS FOR ENHANCING CHECKPOINT INHIBITOR THERAPIES IN CANCER TREATMENT | Purdue Research Foundation (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250352652-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC DISEASE STATES AND CANCER | PURDUE RESEARCH FOUNDATION | 2025-11-20 | — | — | US | disclosed |
| US-20250269036-A1 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | PURDUE RESEARCH FOUNDATION | 2025-08-28 | — | — | US | disclosed |
| US-12397059-B2 | Compounds and methods for the treatment and prevention of fibrotic disease states and cancer | PURDUE RESEARCH FOUNDATION (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2024197318-A2 | COMBINATIONS AND METHODS FOR ENHANCING CHECKPOINT INHIBITOR THERAPIES IN CANCER TREATMENT | PURDUE RESEARCH FOUNDATION (US) | 2024-09-26 | — | — | WO | disclosed |
| CN-117858706-A | Methods of enhancing engineered cell therapies in cancer treatment | 普渡研究基金会 | 2024-04-09 | — | — | CN | disclosed |
| EP-4271378-A1 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | Purdue Research Foundation (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| EP-0777471-B1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING & MFG (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
| EP-0777471-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5612377-A | OXYUREA DERIVATIVE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996003983-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HDAC6 518/4885HDAC1 158/4885HDAC2 666/4885 |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | HDAC6 3764/4885HDAC1 1830/4885HDAC2 3809/4885 |
| US-12397059-B2 | Compounds and methods for the treatment and prevention of fibrotic disease states and cancer | MSR1, MIF, MMP12 | HDAC6 413/4885HDAC1 243/4885HDAC2 526/4885 |
| US-20250269036-A1 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | CD47, FOLR1, CD14 | HDAC6 1103/4885HDAC1 645/4885HDAC2 1006/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | HDAC6 445/4885HDAC1 392/4885HDAC2 647/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | HDAC6 3658/4885HDAC1 1467/4885HDAC2 3372/4885 |
| US-20250352652-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC DISEASE STATES AND CANCER | MSR1, MIF, MMP12 | HDAC6 413/4885HDAC1 243/4885HDAC2 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.